Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer’s Disease Summit

Rhea-AI Summary

Athira Pharma, operating under the ticker ATHA, focuses on developing novel therapies to combat neurodegeneration. On August 25, 2021, Chief Medical Officer Hans Moebius will present at the Annual Biomarkers for Alzheimer’s Disease Summit, highlighting the use of Evoked-Response Potentials (ERPs), specifically ERP P300, in Alzheimer's drug development. This presentation will showcase advancements in non-invasive biomarkers utilized in Athira’s Phase 1 clinical trials.

BOTHELL, Wash., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Chief Medical Officer, Hans Moebius, will present on the application of clinically established Evoked-Response Potentials (ERPs) by using ERP P300 in Alzheimer’s drug development, and the utility of ERP P300 in Athira’s Phase 1 clinical trials, at the Annual Biomarkers for Alzheimer’s Disease Summit taking place virtually August 24-26, 2021.

Presentation Details:

Title: Advances in Direct, Functional, Non-Invasive Biomarkers; Athira’s Utilization of ERP P300
Presenter: Hans J. Moebius, MD, PhD, Chief Medical Officer, Athira Pharma, Inc.
Date: Wednesday, August 25, 2021
Time: 12:10 p.m. PT / 3:10 p.m. ET

About Athira Pharma, Inc.
Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer’s and Parkinson’s dementia. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.

Investor & Media Contact:
Julie Rathbun
Athira Pharma, Inc.
Julie.rathbun@athira.com 
206-769-9219

FAQ

What is Athira Pharma's presentation about on August 25, 2021?

Athira Pharma's presentation will focus on using Evoked-Response Potentials (ERPs), specifically ERP P300, in Alzheimer's drug development.

Who will present for Athira Pharma at the Annual Biomarkers for Alzheimer’s Disease Summit?

Hans Moebius, the Chief Medical Officer of Athira Pharma, will present at the summit.

When is Athira Pharma's presentation scheduled?

The presentation is scheduled for August 25, 2021, at 12:10 p.m. PT / 3:10 p.m. ET.

What is the main focus of Athira Pharma's research?

Athira Pharma focuses on developing small molecules to restore neuronal health and stop neurodegeneration.

What is ERP P300's role in Athira Pharma's clinical trials?

ERP P300 is used as a biomarker in Athira Pharma's Phase 1 clinical trials for Alzheimer's treatment.